
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is a promising company with a positive outlook as their pipeline includes several small molecule products targeting chronic inflammatory and autoimmune diseases. The Phase 3 ENSURE program in RMS for vidofludimus calcium has shown positive results and a reduction in new MRI lesions, indicating potential benefits in terms of relapse and progression reduction. Additionally, vidofludimus calcium offers a unique dual-mechanism of both Nurr1 activation for disease modification and DHODH inhibition for anti-inflammatory effects. However, there may be questions surrounding the long-term impact and efficacy of these treatments.
Bears say
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies for chronic inflammatory and autoimmune diseases. While they are focused on promising therapies, the lack of diversification in their Life Science segment and the potential for the underlying diseases they are targeting to have alternative treatment options causes concern for the success of their lead candidate, vidofludimus calcium, in treating multiple sclerosis. Additionally, the company's financials and projected peak market share may not support its current stock price.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares